Severe and Prolonged Myelosuppression during Concomitant Temozolomide and Radiotherapy Treatment in a Patient with Glioblastoma Multiforme
Claudia Scaringi, Vitaliana De Sanctis, Giuseppe Minniti, Raffaele Porrini, Alessia Carnevale, Maurizio Valeriani, Maria Christina Cox, Maria Antonietta Aloe Spiriti, Giovanna Gentile, Maurizio Simmaco, Luigi Ruco, Agostino Tafuri, Riccardo Maurizi Enrici
International Journal of Medical and Pharmaceutical Case Reports · pp. 95–100 · Published 5 Nov 2014
10.9734/IJMPCR/2015/13957Abstract
Aims: We describe the case of a patient with glioblastoma (GBM) who developed severe and prolonged myelosuppression during concomitant daily temozolomide (TMZ) and radiotherapy (RT) treatment. Analysis of polymorphisms in genes correlated with TMZ-induced myelotoxicity was also performed. Presentation of the Case: A 67–year-old man with diagnosis of GBM undergoing concomitant RT-TMZ treatment developed severe and prolonged pancytopenia that led to discontinuation of TMZ and required frequent platelet and red cells transfusions. Analysis of single nucleotide polymorphisms (SNPs) in the genes NAD(P)H dehydrogenase, quinone 1 (NQO1) and glutathione S-transferase pi 1 (GSTP1) was carried out. Both SNPs were found to be wild-type. Discussion: TMZ is an oral alkylating agent used for the treatment of glioblastoma. TMZ is usually considered well tolerated and safe, with nausea and mild myelosuppression being the most common side effects. However, severe haematologic adverse events have been also reported. Recently, there has been growing interest in gene polymorphisms that might be associated with an increased risk of hematologic toxicity. Conclusion: Myelosuppression is a side effect that can occur relatively early during concomitant TMZ treatment and can negatively impact on patient’s quality of life. Further studies are warranted to find out a correlation between genetic factors and the occurrence of severe hematologic toxicity.
References (14)
- 1 Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma [DOI]
- 2 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [DOI]
- 3 MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma [DOI]
- 4 “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma” [DOI]
- 5 The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1 [DOI]
- 6 Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1 [DOI]
- 7 Hematologic adverse events associated with temozolomide [DOI]
- 8 Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment [DOI]
- 9 Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
- 10 Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide [DOI]
- 11 Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma—analysis of O 6-methylguanine-DNA methyltransferase status [DOI]
- 12 Pharmacology of Oral Chemotherapy Agents [DOI]
- 13 Bone marrow transplantation for severe aplastic anemia secondary to temozolomide [DOI]
- 14 Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial [DOI]
Cited by 0
No indexed citations yet.
Related research
- Advancing Glioblastoma Treatment: Challenges and Opportunities of Immune Checkpoint Inhibition — shares topic coverage
- Prediction of Radiotherapy Dose Distribution for Glioblastoma Using Convolutional Neural Network Model — shares topic coverage
- Microplastics as a Modulator of Oncogenic Gene Expression and Oxidative Stress in Glioblastoma Cancer — shares topic coverage
- Adoptive Cellular Immunotherapy in Glioblastoma: Mechanistic Insights, Clinical Progress, and Future Directions of CAR-T and TIL Therapies — shares topic coverage
- CBX2-Mediated Epigenetic Modulation Drives Proliferation in Gliomas: A Narrative Review — shares topic coverage
Article metrics
Real usage data collected on this platform.
39
Page views
0
PDF downloads
4
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.